| SEC For | rm 4 FORM | 4 | |) STA | TES | S SE | ECU | RITI | ES ANI | DE | ХСНА | NG | E CO | омм | ISSION | | | | | |
|---|---|---|--|--------|---|--|---|--------------|---|-----|--------------------|------------------------------|---|--|--|--|---|--|---|--|
| | | | | | STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 | | | | | | | | | | | | | OMB APPROVAL | | |
| Section 16. Form 4 or Form 5 obligations may continue. See | | | | | | NT OF CHANGES IN BENEFICIAL OWNERSHIP | | | | | | | | | | | OMB Number: 3235-028 Estimated average burden hours per response: 0 | | | |
| Instruc | tion 1(b). | | | File | | | | | a) of the Se Investmen | | | | | 34 | | <u>[]</u> | | | | |
| 1. Name and Address of Reporting Person* BJERKHOLT ERIC | | | | | Ca | 2. Issuer Name and Ticker or Trading Symbol <u>CalciMedica, Inc.</u> [GRAY] | | | | | | | | | Relationship leck all applie X Directo | cable) | 10% Owner | | | |
| (Last) | Last) (First) (Middle) | | | | 3. Date of Earliest Transaction (Month/Day/Year) 03/23/2023 | | | | | | | | | | Officer (give title Other (specify below) below) | | | | specify | |
| C/O GRAYBUG VISION, INC. 274 REDWOOD SHORES PARKWAY, PO BOX 144 (Street) | | | | | | | | | | | | | | Line | Individual or Joint/Group Filing (Check Applicable ne) X Form filed by One Reporting Person Form filed by More than One Reporting Person | | | | | |
| REDWOOD CA 94065 | | | | | Rule 10b5-1(c) Transaction Indication | | | | | | | | | | | | | | | |
| (City) (State) (Zip) | | | | | | | satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10. | | | | | | | | | | | | | |
| | | Tab | le I - Nor | -Deriv | ative | e Sec | curiti | ies Ac | quired, | Dis | posed o | of, o | r Ben | eficia | lly Owned | k | | | | |
| 1. Title of Security (Instr. 3) Date (Month/E | | | | | ar) E | 2A. Deemed Execution Date, if any (Month/Day/Year | | Code (Instr. | | | | | Benefici Owned F | es ally Following | Form (D) o | : Direct r Indirect str. 4) | 7. Nature of Indirect Beneficial Ownership | | | |
| | | | | | | | | | Code | v | Amount | | (A) or (D) | Price | Transac | Reported Transaction(s) (Instr. 3 and 4) | | | (Instr. 4) | |
| Common Stock 03/23 | | | | | 8/2023 | /2023 | | | D | | 1,42 | 1,429 A | | (1) | 1,429 | | | D | | |
| | | T | able II - I (| | | | | | juired, D s, option | | | | | | / Owned | | | | | |
| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year | 3A. Deeme Execution if any (Month/Day | Date, | 4. Transaction Code (Instr. 8) | | | | 6. Date Exercisal Expiration Date (Month/Day/Year | | • | Amo Secu Unde Deriv | 7. Title and Amount of Securities Underlying Derivative Securit (Instr. 3 and 4) | | 8. Price of Derivative Security (Instr. 5) | 9. Numbe derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4) | s Ily | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | Beneficial Ownership t (Instr. 4) | |
| | | | | | Code | v | (A) | (D) | Date Exercisab | | Expiration Date | Title | | Amount or Number of Shares | | | | | | |
| Restricted Stock Unit | (1) | 03/23/2023 | | | D | | | 1,429 | (1) | | (1) | | nmon ock | 1,429 | (1) | 0 | | D | | |

Explanation of Responses:

1. Reflects a 14-to-1 reverse stock split effective March 17, 2023. Under the terms of the Agreement and Plan of Merger and Reorganization, dated as of November 21, 2022, as amended (the "Merger Agreement and right for the stock spin encoded (in 17, 2025, Under the tension of Agreement and right for Merger and Reorganization, dated as of November 21, 2022, as anticed (in 17, 2022, as anticed (in 17, 2023, Merger Sub Agreement"), by and among CalciMedica, Inc. ("Private CalciMedica"), the Issuer and Camaro Merger Sub, Inc., a wholly-owned subsidiary of the Issuer ("Merger Sub"), on March 20, 2023, Merger Sub merged with and into Private CalciMedica (the "Merger"), with Private CalciMedica surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each share of CalciMedica common capital stock was converted into the right to receive 0.0288 of a share of the Issuer's common stock. Subsequent to the Merger, the name of the Issuer was changed from Graybug Vision, Inc. to CalciMedica, Inc. In connection with the Merger, the vesting of Eric Bjerkholt's options and restricted stock units ("RSUs") were fully accelerated and the RSUs were settled on March 23, 2023.

Remarks:

/s/ Robert S. Breuil, Attorney-03/27/2023

in-Fact

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.